Members WC, Ommen SR, Mital S, et al.: 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. A report of the American College of Cardiology/American ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

Hypertrophic cardiomyopathy (HCM ... and the most appropriate investigations for persons suspected of having HCM. Treatment strategies for the disease and its complications are presented briefly.

Looking for reliable medications to treat 'Hypertrophic Cardiomyopathy'? This page offers a detailed resource for the most up-to-date treatment options, including both generic and brand-name ...

Those stages help determine treatment, and they also reflect a patient’s prognosis. Experts say hypertrophic cardiomyopathy is different; it doesn’t play by such tidy rules. “It’s an ...

For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.

With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering ...

TN-201 – Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM ... Phase 1b/2 clinical trial of TN-201 for the potential treatment of MYBPC3-associated HCM in the first half ...

Hypertrophic cardiomyopathy can be difficult to diagnose. But thanks to advancements in treatment, many people can manage their HCM with minimal symptoms. Researchers at OHSU’s HCM Center of ...

Program Updates and Anticipated 2025 Milestones: TN-201 – Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy ... of TN-201 for the potential treatment of MYBPC3-associated HCM ...